{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:26:10Z","timestamp":1740137170220,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T23:38:49Z","timestamp":1719272329000},"page":"2681-2691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-7990","authenticated-orcid":false,"given":"Irem","family":"Eldem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Antunes-Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renumathi","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina M.","family":"Lasky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-2871","authenticated-orcid":false,"given":"Jorge","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-500X","authenticated-orcid":false,"given":"Thomas J.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1073\/pnas.97.10.5255","article-title":"Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa","volume":"97","author":"Camerer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1073\/pnas.141126698","article-title":"Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor","volume":"98","author":"Riewald","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.06.006_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2006-933337","article-title":"Emerging insights in tissue factor-dependent signaling events","volume":"32","author":"Versteeg","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2741\/1796","article-title":"Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit","volume":"11","author":"Chu","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.jtha.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/01.ATV.0000151624.45775.13","article-title":"Tissue factor-factor VIIa signaling","volume":"25","author":"Rao","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1042\/CS20040237","article-title":"Factor VIIa stimulates endothelin-1 synthesis in TNF-primed endothelial cells by activation of protease-activated receptor 2","volume":"108","author":"Sethi","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jtha.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1160\/TH05-01-0002","article-title":"Differential gene expression in activated monocyte-derived macrophages following binding of factor VIIa to tissue factor","volume":"94","author":"Muth","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/ATVBAHA.107.142539","article-title":"Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis","volume":"27","author":"Uusitalo-Jarvinen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood-2003-09-3051","article-title":"Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia","volume":"103","author":"Pawlinski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1016\/S0021-9258(18)68737-X","article-title":"Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains","volume":"263","author":"Wun","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.06.006_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.CIR.0000078642.45127.7B","article-title":"Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"Dahm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V78.2.387.387","article-title":"Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples","volume":"78","author":"Novotny","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.ATV.15.4.504","article-title":"Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia","volume":"15","author":"Kokawa","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib15","first-page":"551","article-title":"Heterogeneity of plasma tissue factor pathway inhibitor","volume":"5","author":"Broze","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1172\/JCI69091","article-title":"Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPI\u03b1","volume":"123","author":"Vincent","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.06.006_bib17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V72.6.2020.2020","article-title":"Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor","volume":"72","author":"Novotny","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/ATVBAHA.120.315728","article-title":"Major reservoir for heparin-releasable TFPI\u03b1 (tissue factor pathway inhibitor \u03b1) is extracellular matrix","volume":"41","author":"Peterson","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtha.2022.11.033","article-title":"Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease","volume":"21","author":"Girard","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.jtha.2024.06.006_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1538-7836.2008.03033.x","article-title":"Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans","volume":"6","author":"Maroney","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/jth.14288","article-title":"Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology","volume":"16","author":"Girard","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/338518a0","article-title":"Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor","volume":"338","author":"Girard","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.06.006_bib25","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1073\/pnas.0504240103","article-title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor","volume":"103","author":"Hackeng","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtha.2024.06.006_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/blood-2009-10-246686","article-title":"The Kunitz-3 domain of TFPI\u03b1 is required for protein S-dependent enhancement of factor Xa inhibition","volume":"116","author":"Ndonwi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1538-7836.2008.02980.x","article-title":"Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor","volume":"6","author":"Ndonwi","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2011-10-388512","article-title":"TFPI\u03b2 is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes","volume":"119","author":"Girard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/j.1538-7836.2005.01636.x","article-title":"Comparison of cell-surface TFPIalpha and beta","volume":"3","author":"Piro","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0049-3848(87)90154-X","article-title":"Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins","volume":"46","author":"Hubbard","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.006_bib31","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1016\/S0021-9258(18)51542-8","article-title":"Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma","volume":"264","author":"Novotny","year":"1989","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0049-3848(91)90365-4","article-title":"Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI","volume":"62","author":"Lindahl","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.006_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0049-3848(97)00029-7","article-title":"Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in\u00a0vitro","volume":"85","author":"Hansen","year":"1997","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-0038-1657571","article-title":"Tissue factor pathway inhibitor: clinical deficiency states","volume":"78","author":"Sandset","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1538-7836.2005.01237.x","article-title":"A\u00a0novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)","volume":"3","author":"Dahm","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.06.006_bib37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hoc.2021.07.007","article-title":"Acquired hemophilia A","volume":"35","author":"Pai","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtha.2024.06.006_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/asheducation-2013.1.44","article-title":"The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders","volume":"2013","author":"Ragni","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.06.006_bib39","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib40","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.06.006_bib41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.06.006_bib42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.06.006_bib43","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.06.006_bib44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.06.006_bib45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.06.006_bib46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.06.006_bib47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood.V90.3.944","article-title":"Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib48","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1073\/pnas.1119858109","article-title":"Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia","volume":"109","author":"Maroney","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.06.006_bib49","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/jth.15430","article-title":"The contribution of TFPIalpha to the hemostatic response to injury in mice","volume":"19","author":"Marar","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.14337","article-title":"Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A","volume":"17","author":"Girard","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib51","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/01.ATV.19.10.2563","article-title":"Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat","volume":"19","author":"Han","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-0037-1615666","article-title":"A\u00a0tail vein bleeding time model and delayed bleeding in hemophiliac mice","volume":"85","author":"Broze","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib53","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1126\/science.1972598","article-title":"Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein","volume":"248","author":"Girard","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.06.006_bib54","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2014-08-592733","article-title":"A\u00a0novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function","volume":"125","author":"Cunha","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib55","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jth.15314","article-title":"F5-Atlanta: a novel mutation in F5 associated with enhanced East Texas splicing and FV-short production","volume":"19","author":"Zimowski","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib56","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V120.21.1104.1104","article-title":"Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499","volume":"120","author":"Dockal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.006_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.06.006_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4899-2444-5_20","article-title":"Tissue factor pathway inhibitor and heparin","volume":"313","author":"Abildgaard","year":"1992","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jtha.2024.06.006_bib59","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/rth2.12057","article-title":"Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIalpha) cofactors","volume":"2","author":"Dahlback","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.006_bib60","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jth.12201","article-title":"Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein","volume":"11","author":"Waters","year":"2013","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:53:24Z","timestamp":1739498004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624003635"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.006","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}